Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes.
Analyst Commentary
Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines. Analysts are increasingly focused on the durability of the companys immunology franchise, the earnings impact of extended Rinvoq exclusivity, and the broader rerating potential for large cap biopharma.
Bullish Takeaways
- Bullish analysts highlight that strong execution in Skyrizi and Rinvoq, combined with extended Rinvoq exclusivity into the mid 2030s, supports a longer runway for high margin growth and is cited as justification for targets in the mid 240 to low 260 dollar range.
- Several target hikes emphasize AbbVie as a core large cap holding, citing improving visibility on post Humira growth, better than expected Q3 fundamentals, and rising confidence that consensus underestimates medium term revenue and EPS trajectories.
- Supportive views on the broader biopharma sector, including the idea that multi year underperformance creates an attractive entry point ahead of the next innovation cycle, are viewed as an additional valuation tailwind for AbbVie.
- Partnerships and pipeline exposures, such as oncology and immunology collaborations, are framed as underappreciated optionality that could add incremental royalty and milestone upside to current models.
Bearish Takeaways
- Bearish analysts moving to Hold argue that, after the recent rerating and multiple target increases, much of the Rinvoq settlement benefit and near term guidance strength is now reflected in the share price.
- Some remain cautious on execution risk around pipeline investments following a notable research and development write off, which raises questions about capital allocation discipline and long term return on investment.
- There is lingering concern about pockets of softness in legacy assets and aesthetics, which could cap multiple expansion if growth from newer therapies does not consistently offset these headwinds.
- Neutral stances also reflect macro factors, including policy and pricing uncertainties, with some seeing limited upside relative to risk after the stocks recent outperformance versus the broader healthcare complex.
What's in the News
- AbbVie is ending its decade long drug discovery partnership with Alphabet funded Calico Life Sciences and will lay off chemists tied to the collaboration, marking a strategic reset in its external early stage research portfolio (STAT).
- DZ Bank downgraded AbbVie shares from Buy to Hold with a 237 dollar price target, signaling perceived limited upside after the recent rerating.
- AbbVie joined a pharma consortium with Bristol Myers Squibb, Takeda and Astex to pool structural biology data for training an AI model aimed at accelerating drug discovery and development (Reuters).
- AbbVie secured full FDA approval for EPKINLY in combination with rituximab and lenalidomide in relapsed or refractory follicular lymphoma, based on Phase 3 data showing a 79 percent reduction in risk of disease progression or death versus standard of care.
- The company announced a 5.5 percent increase in its quarterly cash dividend to 1.73 dollars per share starting with the February 2026 payment, reflecting its ongoing focus on returning capital to shareholders.
Valuation Changes
- Fair Value: Unchanged at approximately 243.55 dollars per share, indicating no revision to the intrinsic value estimate.
- Discount Rate: Risen slightly from about 7.28 percent to 7.32 percent, reflecting a modestly higher required return on equity.
- Revenue Growth: Edged down marginally from roughly 8.13 percent to 8.09 percent, signaling a slightly more conservative top line outlook.
- Net Profit Margin: Increased modestly from about 29.67 percent to 29.81 percent, implying a small uplift in expected profitability.
- Future P/E: Ticked down slightly from around 23.83x to 23.77x, suggesting a marginally lower valuation multiple applied to forward earnings.
Have other thoughts on AbbVie?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.